Metabolic changes after H(2) 15O-positron emission tomography with acetazolamide in a patient with moyamoya disease: case report and review of previous cases.
Perioperative ischemic complications not directly related to surgery require special attention in patients with moyamoya disease; positron emission tomography (H(2) 15O-PET) and single-photon emission computed tomography have been considered indispensable for evaluating pre- and postsurgical cerebral hemodynamics. The clinical records of 14 patients with moyamoya disease who underwent 26 extracranial-intracranial bypass operations were reviewed with special reference to perisurgical complications. One patient developed multiple postoperative ischemic infarctions and died of ischemic brain edema. The history of this patient with prolonged acidosis is analyzed, and the role of metabolic changes induced by H(2) 15O-PET with acetazolamide challenge is reviewed. Seven (77.8%) of nine patients operated on within 48 hours after H(2) 15O-PET with acetazolamide (group 1) developed metabolic acidosis, whereas only three (17.6%) of 17 patients operated on >48 hours (group 2) after the examination had intraoperative pH of <7.35. In group 1, the mean intraoperative pH was 7.328, which was significantly lower than the mean pH of 7.393 (P <.0001) in group 2. After H(2) 15O-PET with acetazolamide challenge, patients must be carefully observed concerning acidosis and volume state. We recommend at least 48 hours between examination and surgery for patients with moyamoya disease so that their conditions can stabilize. Furthermore, special care should be taken to avoid additional perioperative risk factors such as hypotension, hypocapnia, hypercapnia, and hypovolemia.
Muroi
Carl
C
Department of Neurosurgery, University Hospital Zurich, Zurich, Switzerland. ees@nch.unizh.ch
Yonekawa
Yasuhiro
Y
Khan
Nadia
N
Pangalu
Athina
A
Keller
Emanuela
E
D000086:Acetazolamide / Q000009:adverse effects*; D000138:Acidosis / Q000378:metabolism; D000328:Adult; D001794:Blood Pressure; D002339:Carotid Arteries / Q000000981:diagnostic imaging; D002533:Cerebral Angiography; D002548:Cerebral Revascularization; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007431:Intraoperative Complications / Q000503:physiopathology; D009072:Moyamoya Disease / Q000000981:diagnostic imaging* / Q000378:metabolism*; D010104:Oxygen Radioisotopes / Q000009:adverse effects*; D010291:Paresis / Q000150:complications / Q000000981:diagnostic imaging; D011183:Postoperative Complications / Q000209:etiology; D019275:Radiopharmaceuticals / Q000009:adverse effects*; D012640:Seizures / Q000209:etiology; D014055:Tomography, Emission-Computed / Q000009:adverse effects*
D010104:Oxygen Radioisotopes; D019275:Radiopharmaceuticals; D000086:Acetazolamide